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My capstone project anaJyzes the crisis of retirees on a fixed income due to high pharmaceutical costs. 
I hoped to prove that the opinion that there exists a state of crisis that is being popularized by politicians 
and the media is really just existing at the individual level rather than a widespread epidemic. I believe that 
the "crisis" is being exploited for political gain, as there can be painted a clear "good guy/bad guy" 
situation, with the phannaceutica1 companies being the latter. Additionally, the AARP-age group is a strong 
supporter to have on one's side in politics. Politicians arc playing to this fact and arc proposing policies that 
disregard the economic repercussions that will surely be suffered through their attempts to cap prices and 
restrict the pharmaceutical industry. In their efforts to win support from this influential group of aging 
Americans they will, in the end, harm them. 
For my literature review, I have chosen thirteen articles on the topic of drug costs and their effect upon the 
elderly. The majority of these articles review the current political climate and the propositions before our 
government to rectify the skyrocketing costs of prescription drugs. 
Of the thirteen articles, twelve take the stance that those on a fixed income arc suffering. They arc the 
most in need, thus, those most affected. The pharmaceutical industry comes out looking the greedy, bad 
guy, and there must be legislation put in place to regulate their actions. Each article; however, puts a 
different twist on the information, with some siting failings of statistics, others looking at specific diseases, 
etc. They differ enough from each other to keep the reading both interesting and insightful. 
There is one piece; however, which takes on an entirely different viewpoint on this situation, "Our 
phoniest drug war," by Doug Sandow. This article made this assignment all the more interesting. After 
reading and reviewing one dozen articles which presented the same problems, arguments and conclusions, I 
got to lucky number thirteen - a relatively short piece which makes the bold statement, "there is no crisis." 
The following is a summary of each piece: 
I. "How Medicare beneficiaries pay for prescription drugs" 
This article outlines the sources of the crisis of drug costs and the elderly. 
For retirees, most health benefit supplements come from employer-sponsored health plans. These 
generally impose steep co-pays for prescription drugs. The percentage of employers offering any retiree 
benefits is steadily declining, and those remaining are requiring that retirees pay a substantial part of their 
premium. Many of these employers are also requiring that retirees sign up for the Medicare+ Choice plan, 
which is very restrictive in their drug coverage. Still others "carve-out'' drug benefits, offering them at a 
separate premium. Those retirees with no employer program can purchase the Medigap supplement to 
Medicare, where prescription benefits carry a high deductible and copay as well as a benefit cap. The 
elderly poor rarely have employer-sponsored benefits and cannot afford to purchase Medigap policies; - 
however, Medicaid is available to those who qualify. There exists a real problem for those who lose or try 
to switch coverage, falling into a gap ofno coverage at all. Coverage has proven to be very unstable. 
The article goes on to provide Web sites that provide useful information on coverage, such as "Medigap 
Compare," and "HFCA." 
2. "Restricting drug choice can increase health care usage" 
This article presents the findings of a survey conducted at the Institute for Clinical Outcomes Research of 
the School of Medicine, University of Utah, regarding prescription spending. 
The questions asked were not new ones: "who spends more, younger or older patients, for what ailments 
and generic versus high cost." The conclusions presented were not unexpected: younger patients spend 
less and on fewer prescriptions per year. Of the studied diseases, arthritis, heart disease, etc., the elderly 
received more prescriptions. It was also concluded that if access to drugs were limited, the elderly would be 
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more affected, except in the case of asthma. The study also found that increased usage of generic drugs 
resulted in even higher costs among the elderly. Generics use is not cost-containment appropriate for the 
elderly. 
This last conclusion was the one I found most interesting; however, neither the article nor the study 
explained why generics caused higher costs. Th.is would have been a fresher point to elaborate upon, since 
generics are traditionally used to cut costs. Why does this fail in this age group? 
The use of generics will be discussed again later in my review. 
3. "Drug pricing "powder keg" stirs up US health-care politics" 
Th.is piece looks at both sides of the pharrnaceutica1 cost argument. 
The phannaceutical industry contends that its products are a "wondrous bargain, well worth their rising 
prices because of the therapeutic benefits they confer for conducting costly research for even better drugs." 
The consumer and political sides argue that the costs are a burden on needy patients. 
The author sites a study by the Library of Congress that finds that due to tax breaks, after-tax profits for 
the phannaceutical industry averaged 17% of sales, while other industries weighed-in at just 5%. The 
industry defends itself against this finding, stating that these tax breaks are received because they invest 
heavily in much-needed research and development. 
The industry is fearful, says the author, of the inevitable price controls and rising antagonism towards 
them. The elderly are the hardest hit by the high prices, but they are politically well organized, and arc 
"courted by office- seeking politicians." 
4. "Editor's PicK' 
This piece asks the questions: "ls there a maximum amount of profit that companies should earn?" 
And, "Should our elderly, the most medication-dependent sector of society, be held hostage to corporate 
greed?" 
Its answer is to blame drug companies for creating unnecessary demand for their products through direct­ 
to-consumer advertising. "$905 million was spent by the industry in the first half of 1999 alone, up 43'/o 
from the prior year." The author contends that these ads change the physician-patient relationship, creating 
fear and demand in the patient, who in turn demand the prescription from their doctor. Rather than argue, 
the doctor usually complies. 
Do these ads empower the patient? Are they a consumer service as argued by the industry? The author 
does not support this defense, and believes that urgent action is needed to curtail this excess of the drug 
industry. 
This is an interesting approach, I think, to blame advertising. My question after reading this article is, how 
does this differ from any other industry that puts a commercial on TV in order to influence perspective 
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customers? I personally cannot sec why any industry docs not have the right to promote their product via 
mass media. 
5. "Bitterpil/s" 
This article sites the statistic that one in three seniors have no drug insurance. It goes on to say that in the 
US, prescription costs arc the highest in the world - nearly twice what Europeans and Canadians pay for 
the sune drugs. 
Drug makers claim that prices have risen due to several factors, such as: new medications are 
''breakthrough" drugs which arc helping people to live longer; the number of years it takes to bring a drug 
to the market; due to price controls abroad, they arc forced to make up the difference in this country; the 
increase in outpatient services, where most policies do not cover prescriptions as opposed to inpatient care 
where these same drugs are covered. 
The industry believes that drug prices have become a political topic, as it is easy to exploit the "good 
guy- bad guy" scenario in this issue, and that possible drug-price cutbacks will take their toll on research, 
especially in rare diseases. They also fear that federal dollars used to fund drug benefits will mean cuts 
elsewhere in healthcare, as federal funds are finite. 
Much like in the article presented, "Editor's Piclc," this piece also places blame upon the rising awareness 
of patients due to direct advertising by the pharmaceutical industry. New Zealand and the US are the only 
nations that currently allow such advertising. 
6. "Prescription drug spending: The impact of age and chronic disease status" 
The authors here open their piece with this statistic, which sums up the nature of the elderly- drug cost 
crisis: 
" ... The elderly account for 34% of total phannaccutical. expenditures, although they make up 12% of 
the population," and they further conclude that, "significant pharmaceutical spending is for the treatment of 
chronic conditions ... " 
Chronic disease is the most important detenninant of drug expenditure. Among the elderly, 36%, state the 
authors, had three or more chronic conditions and accounted for 57% of drug spending by this age group. 
Of these conditions, arthritis and hypertension arc the most common. The highest spending is for the 
treatment of diabetes, emphysema, and heart disease. 
The findings of the authors also show the importance that outpatient services have upon expenditures. The 
data also indicate how drug use is distributed nationally by therapeutic class. Additionally, they've found 
that patients arc more responsive to increases in drug prices as they affect their budget more and this causes 
changes in behavior. This infonnation can be used selectively in benefit design. 
In general, I found the conclusions presented by this study confusing and difficult to understand. The data 
on therapeutic classes and cost shifting were not made clear enough to the reader. 
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7. "Prices, patients, risks and research" 
" .... the appearance of expensive new therapies is dividing the population into the "haves" with insurance 
coverage of prescription drugs and the "have nots" .... " Many seniors, the author points out, fall into the 
"have nots." This fact is putting pressure upon Congress to provide Medicare, outpatient drug benefits. 
Much like the earlier reviewed article, "Drug-pricing powder keg," this piece argue5 that price regulation 
will take its toll on research and development, thus hurting these same consumers in the end. 
The article goes on to describe various plan options, such as "catastrophic" plans which target chronic and 
specific diseases only, incremental approaches, and broad plans with copays and deductibles. A major 
problem, as pointed out by the author, is that these plans will increase government influence over prices. 
Additionally, manufacturers would be under pressure to get on "preferred lists" of formulae. 
There is also the problem with generics, where the government is pressuring the FDA to approve these 
lower-cost drugs faster. However, if we go back to the earlier -reviewed article, "Restricting drug choice 
can increase health care usage," the authors there concluded that generics do not contain costs for the 
elderly. If you take this as fact, this government measure will not help the group it is intending to relieve. 
The FDA, in tum, is actually seeking to increase their efforts to reduce risks and improve quality in drugs, 
including generics, by tightening their standards of evolution. They are taking a "safety first" approach, 
which the author supports. They are also seeking to protect consumers from less-expensive Internet 
purchasing, where product quality is questionable. 
8. "States' Rx/or drug costs" 
In this piece, the author explores how different states arc working to curtail the hardships placed upon the 
elderly by increasing drug prices. The opening statement illustrates the crisis, as it describes a 67 
year-old women who has had to return to work in order to pay her $469 per month ulcer medication 
bills. Another story is of a Florida rctircc who spends nearly one-half of her yearly-fixed income on her 
prescriptions for a lung ailment. Florida offers no drug-coverage plan. 
An example of one state that is working to ease such suffering is Maine, where the "Low Cost Drugs for 
• 
Toe Elderly'' program went into effect in 1999, and now pays 800/e of the costs for those in need. Maine has 
the nation's first law that includes price controls on prescriptions. Maine also created the "Maine Rx" 
program which allows any resident without prescription coverage to purchase drugs at a discount, which is 
based upon Medicaid rates. However, this program has been challenged in court by the pharmaceutical 
industry and could set precedent for programs in other states. 
As of December 1999, 16 states had some fonn of drug assistance for seniors. By 2000, this had 
increased to 22. Other states, such as Iowa and New Hampshire, have initiated buying "clubs" offering a 
discount These subsidies are being funded by tobacco-settlement funds. Maine, New Hampshire, and 
Ycnnont has instituted a joint "pharmacy - benefits manager," who will create educatiom,.J 
programs for doctors and patients in cost effective medical regimes. The author points out that such state 
programs are costly and that this is preventing many states from setting up similar state-funded plans. Many 
s 
opponents believe that this issue is not one that should be dealt with on a state level and must be a federal 
one, siting that a "patchwork" of state plans will create chaos in the phannaccuticaJ industry. 
I found this article quite informative. Instead of painting a11 of the negatives and crises, it presents various 
positive approaches which the states arc attempting. The sidebars also do a fine job of summarizing various 
state's actions. 
9. "Persistence of use of lipid-lowering medications: A cross-nationa/ study" 
When I came across the title of this article, I thought it was about a specific medical study, rather than an 
investigation into drug/price effects on the elderly. As I read on; however, I found it a piece useful to my 
review, because it shows how patients failed to continue their regiment of lipid-lowering medications due 
to the costs involved. It additionally shows how their health suffered because of this. These lipid-lowering 
drugs arc used by patients at the highest risk for cardio-vascular disease, namely the elderly, poor and 
minorities. This piece is the best illustration of the crisis of prescription costs and the elderly that I've come 
across, as it is very specific, showing the regiment necessary to maintain health and the effects caused by 
disruption in this regiment. 
The studies were described fully, coming to the conclusion that the lower the income level, the higher the 
rate of noncompliance. The data were adjusted for such contributing factors as side effects and 
inconvenience. In fiscally generous insurance systems, compliance was highest. The more cost out-of­ 
pocket, the lower the compliance. 
10. "The price isn't right" 
This article makes an interesting opening statement," ... astronomical prices arc rooted in govemment­ 
funded research, necessitating that government policy needs to bring prices and research priorities 
down to earth." 
The author explains that private-sector labs claim to be responsible for breakthroughs in drugs. This is 
their great defense - limit prices and you will "short circuit the current medical revolution." But, this 
defense falls short. The author states that every independent study that investigates sources ofmodical 
innovation comes to the conclusion that it is public-sector research, not private, which has lead to the 
majority of significant advances. To support this, the author tells the story of a boy with Gaucher disease, a 
genetic disorder. The price of treatment of this ailment is nearly one quarter of a million dollars per year. 
The technology to treat this is government developed, from the National Institutes of Health. The 
government; however, transferred the intellectual property to a private company, which now produces the 
treatment. And, this scenario is not a unique one. 
A 1997 National Bureau of Economic Research study showed that public research led to 15 of the 21 
drugs considered having the highest therapeutic value introduced between 1965 and 1992. The same 
study also found that 60% of 32 innovative drugs would not have been discovered or would have taken 
longer to discover without research contributions from government labs and noncommercial institutions. 
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In other words, it is the taxpayer that is funding research, not the pharmaceutical manufacturers. In 
fact, the author says, most of the research by private labs is aimed at stealing marketshare from competitors 
or replacing their own products coming off patent. 
The author blames the government's inability to track tax-payer funded research, and adds that if the 
government was to increase public funding of research, they could control prices without the feared effects 
on research and development. 
I found this article extremely interesting. Much of my other reading speaks of the industry defense 
concerning research and development, but this author completely tears that apart, putting research 
funding in a whole new light. That's precisely why I chose this article for review. 
11. "Prescription drugs and the elderly: Issues and options" 
This article states many of the points of crisis and the supporting statistics that my other article choices 
used to describe the problem of drug costs and the elderly. I feel no need to review those again; instead, 
focusing on the public policy options presented by the author. 
If prescription drug coverage for the elderly were to be extended, there arc issues that need resolution, 
namely, "Who?" "What?" and "Who will pay for it?'' The author outlines four policy options to answer 
these questions. 
a.) Encourage state pharmaceutical assistance programs. Offering matching grants will encourage more 
states to develop assistance programs for those not covered by Medicaid. The advantage is that it 
could be targeted at the lowest-income elderly and would allow state discretion. The disadvantage is 
that both the federal and state governments need to find funding for this program. 
b.) Require all Mcdigap policies to cover prescription drugs. The advantage here is that it will eliminate 
the possibility of adverse selection, assuring fair, stable benefits. The disadvantage is that this will 
not cover the elderly without supplemental coverage. Also, th«e exists no contnbution to cost 
containment. 
c.) Extend Medicare benefits to cover prescription drugs while reducing the deductible to a more 
affordable level. The advantage is that enrollment could be more universal and that the concentrated 
market power of Medicare could be used to contain costs. The disadvantage is that it could lead to 
redistribution of income from those who have coverage to those who don't Also, it will substitute 
public financing for private. 
The author concludes that there needs to be a better understanding for more infonncd debate before any 
options can be chosen. 
12. "Making sense of drug prices" 
In this article, the author makes and defends the following statement: 
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"Any form of price regulation, including the setting of uniform prices within the United States or cross· 
nationally, would discourage innovation and competition. The best way to make drugs more affordable for 
the elderly would be to allow them to choose among competing private sector plans." 
The author contends that studies that present drug price as higher in the US than other countries arc 
flawed. First, because the study samples include only leading branded products and did not consider 
generic substitutes. Second, the studies did not account for volume discounts in the US. And, third, because 
arithmetic averages were calculated using unweighted averages. If these items were corrected, the author 
believes studies would show that US drug prices arc far from the highest in the industrialized world. 
It is also suggested that studies of domestic prices arc flawed as well. The House Committee on 
Government Reform and Oversight reached misleading conclusions, mainly because they compared retail 
prices to Federal Supply Schedule prices. These prices arc at "different levels of the distribution chain," 
and cannot be fairly compared, as the FSS involves favored.customer discounts. 
Another misconception involves proposed plans that will offer a discount to elderly customers. If 
discounts were to be given to elderly cash -paying customers who do not participate in a managed 
program, how would it be done? Since they purchase directly from a pharmacy, manufacturers would have 
to provide the pharmacy with a discount. There is no assurance that these discounts would then be passed 
along to customer. 
Going back to the opening quote, the author believes that competition would be the best answer to the 
elderly problem. Customers could select programs based upon their preferences and cur-of-pockee costs. 
Competition would regulate the prices. It is concluded that rather than focus on the profits of 
pharmaceutical manufacturers, we would be better served looking at laws, regulation and taxes that would 
encourage healthy levels of research and development investment. 
13. "Ourphoniestdrugwar" 
This article describes the "lack" of a problem with drug prices. The author goes as far as to say, ''There is 
no crisis." 
"The biggest complaint about prescription drugs is the cost, even though Americans devote more money 
to alcohol and almost as much to tobacco." This statement sums up the attitude of the author. 
He sites analysts William Orzechowski and Robert Walker, saying that 70% of the elderly spend less than 
$.500 per year on pharmaceuticals and only 4% spend more than $2,000 per year. Also, that two-thirds have 
some sort of coverage for pharmaceuticals. 
He agrees that phannaceutical spending has increased, but that this had lead to the mispcrccption of 
runaway prices. The increase, he explains, is in total outlay, not average price. Government estimates arc 
flawed due to poor sampling, ignoring generics, falling new-drug prices, and drug quality. 
The author goes on to blame the FDA regulations for as much as doubling the cost of new drugs. He adds 
that any new drug policy would inflate demand and spending and lead to price and use controls. 
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It is concluded that the government should "do no harm." By destroying the phannaccutic:al industry, no 
one would get financial relief. 
While I'm not sure I can agree with the positions taken by the author, the article does make me question 
the current state of drug costs on the elderly and the propositions before government to correct the 
situation. This author and his stance is most in line with the stance that I have taken on this issue, that there 
docs not exist a wide spread crisis and reigning in the pharmaceutical industry will serve no one. 
In conclusion, after looking at the summaries of these collected readings, it is evident to me, with the 
exception of the last piece, that the authors believe something must be done to aid the crisis of drug costs 
and the elderly. It is debatable how dire the actual crisis is, as the data available is believed to be flawed. 
Each article presents different causes and different options to correct the problem, but there exists 
agreement that those currently before Congress arc under too much outside influence to be properly 
designed. Options will have negative repercussions if great care isn't taken in their design. Policy cannot 
serve all parties. 
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To support my stance on the issue of drug costs and those on a fixed income, my chosen methodology was 
to first administer a survey to the group in question, namely retirees. This would give me a good statistical 
basis to prove or disprove my point I also sent out interview-type questionnaires to subjects functioning in 
different arenas in healthcare, namely healthcare provider, pharmaceutical representative and elected 
officials from the sample community. This would provide an opportunity to compare and contrast the 
beliefs and attitudes of these varying subjects. 
In May of 2001, I met with the Cedar Grove New Jersey Senior's Club to administer a survey discussing 
the problem retirees on a fixed income face regarding the high cost of prescription drugs. I chose this group 
because all members must be over 55 years old and retired. They are aJso members of one geographic 
community, which is for the most part typical of suburban New Jersey. By administering this survey, I was 
hoping to establish the level of"crisis" that existed within this community regarding their situation with 
high drug costs. A copy of this survey can be found in Exhibit 5. 
Cedar Grove, where this sample was taken, is a small suburb of 11,731 people located in Northern New 
Jersey. Those 65 years and older account for 21.23% of it's population. Nearly 95% of the population is 
white. With a median household income of over $55,000 and only 332 persons living in poverty, it could be 
said that this town is moderately affluent. It should be noted that Cedar Grove is home to a county hospital 
where many of those labeled as impoverished reside. A table of demographics is provided in Exhibit I. 
Of the 90 surveys administered, 62, or 68.89% were returned. The questions focus upon the medical 
history of the participants and the type of coverage they hold, as well as the personal affect drug costs have 
had on their lifestyle. The participants were instructed too not respond to questions that they felt invaded 
their privacy or made them feel uncomfortable. 
Of those sampled, the average age was 75 years old. 68% were female and 32% male. The average length 
of residence was 36 years. The average rate number of years retired was just over 12. 
In looking at these statistics along with my observations from our meeting, I would say that the majority 
of the sample were outgoing and involved and had lived in the community long enough to establish a 
support network of friends. I believe this important because these people were not isolated, but active 
members, as opposed to being homebound and of poorer health, which would have skewed the data. 
The first question concerning health asked, "For what conditions do you regularly take prescription 
medication?" This question was trying to establish the routine involved with the sample's prescription costs. 
The results are illustrated in Exhibit 2. The majority, at 41 %, regularly take drugs for high blood pressure. 
This was followed with 21 % for "Other." The majority of conditions listed under "Other" were for 
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cholesterol and thyroid related conditions. Heart conditions (I 7%), glaucoma (5%), diabetes (4%) and 
depression (3%) followed these. 
The next question assessed the general health of the sample, by asking what chronic diseases they suffer 
from. This response is illustrated by Exhibit 3. The majority, at 30%, suffered from heart conditions. This 
was followed closely by arthritis at 26%. The remaining disorders were cancer (I 5% ), respiratory ailments 
(13%), other (8), stroke (5%) and glandular (3%). The "Other" consisted of disorders such as reflux and 
aneurysms. 
The next group of questions centered on the sample's insurance coverage, in an effort to illustrate how 
much coverage the group had, why they chose their plans and the costs involved. It also looked for lapses 
in coverage, such as too few participants holding MediGap policies. 
When asked if they canied traditional Medicare or HMO's, a large majority, 86%, participated in 
traditional Medicare. When citing their reasons for this, most replied that they distrusted HM O's, and that 
they wanted freedom to choose their own physicians. Most of those who chose HMO have cited their 
reason as being that this was the plan provided by their employer upon retirement. Many did not like the 
fact that HMO's did not allow a patient to choose their own physicians. 
Perhaps, due to the ages of the participants, they have had little experience with HMO's, as they are a 
relatively new choice. Their feelings of distrust and unreliability may stem from this, as well as dislike of a 
system that places restrictions on their care. The younger generations are more comfortable with HMO's as 
they have been raised in a culture that supports their use. 
When asked if they carry a McdiGap policy, 53% stated that they did not. Of the 47% that did cmy this 
coverage, the average price paid per month was $96. It is important to note that many of the participants 
with MediGap received it free or substantially subsidu.od as part of their retirement package, thus skewing 
the results. If these outliers are removed, the average monthly price paid is $127. The main reason cited for 
carrying this additional coverage was that it supplements Medicare. For those on a fixed income, coverage 
at this price could be difficult to afford, and the fact that nearly half of the sample did carry it was 
surprising. I expected that fewer could afford it's high premium. 
The final group of questions asks about the choices made and hardships endured due to the cost of 
prescriptions. The results can be reviewed in the graph in exhibit 4. 
The first question asked, ''Have you ever not filled a prescription due to its cost?" 85% of the sample said 
''No." 
The second question, "Have you ever rationed your medication to make your prescriptions last longer?" 
was answered "No" by 8'1°/t of the sample. 
The results of the third question were similar, "Have you ever postponed paying bills or reducing food 
outlays due to the cost of your medication?" 94% said ''No", they have not. 
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Those who answered "Yes" to these questions were obviously in the vast minority; however, in a town with 
this level of affluence and in a group with this level of insurance coverage., the fact that there were those 
who do have to make these sacrifices in order to pay for their medications was surprising. One of the 
participants added commentary to their answers, stating that ... "although they themselves had no problems 
associated with their prescription costs, that they knew of others in the community who did, and they felt it 
was a disgrace and wanted something done to prevent this from happening." 
I was very satisfied with the results of this survey. I felt the conclusions derived at from the sample 
provided great insight into the state of"crisis" regarding prescription drug costs. The participants were 
more than willing to be a part ofmy study, leading me to believe that politicians should go to their 
constituents more often before fonning their own opinions on this topic. Perhaps then any legislation 
presented and/or voted upon would be better designed and more serving of all parties involved. 
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For the next part ofmy analysis of the effects of prescription drug prices, I looked to the various articles 
that I presented in my literature review. Of the thirteen, all asked essentially the same questions; yet, 
depending upon the point of view of the author took different stances. Is there or is there not a crisis? Who 
caused the crisis? Will price cap policies do more harm than good'? And, what should a federal policy 
include? 
I prepared a questionnaire/interview using these four questions, then presented them to six interviewees, 
each coming from a different arena. The aim was to compare the responses of each for differing opinions 
based upon their participation in Healthcare. By looking at the varying perspectives, I was searching for 
any agreement on the issues, as well as looking to see how differing arenas influence these opinions. 
One questionnaire went to a representative of the pharmaceutical industry, Ms. Yolanda Burdsy, Quality 
Assurance Specialist The second went to Dr. Veronica Santilli, practicing physician, President of a large 
pediatric practice and member of the Board of Empire Blue Cross Blue Shield. The third went to a 
healthcare administrator, Dr. Raul M. Abad, Vice President of Medical Affairs for Easton Hospital in 
Easton, Pennsylvania. For the last group of three, I thought it important to get the opinions of elected 
officials that represent the geographic sample. As political figures, it is this group who could at some point 
be voting on actual legislation regarding drug policies. One went to the Town Council of Cedar Grove and 
was answered by the Mayor's Office, another went to Acting New Jersey State Senator Kevin J. O'Toole, 
and the last was sent to the offices of House Representative Bill Pascrell of New Jersey who also represents 
Cedar Grove. Their responses are as follows: 
Looking first to Yolanda Burdsy- Pharmaceutical Quality Assurance Specialist 
1. Do you believe that there does or docs not exist a state of crisis regarding prescription drug prices and 
their effects upon those on a fixed income? Why or Why Not? 
Although it is no surprise thaJ drug prices are progressively increasing due to many driving 
factors in the changing paradigm of hea/thcore delivery a state of crisis is truly a concept thaJ 
may be defined accordingly through the eye of the beholder. The effect of sharply rising drug 
prices upon those individual withftxed income may be q11ite devastating. However, governments 
that impose price controls and other market interventions delay research and limit access to new 
drugs and therapies; and if comwners throughout the world remember that governments which 
impose price controls are not getting what they bargained for they will put into perspective that an 
increase in drug price is necessary to facilitate the research, production, and distribution that is 
needed accordingly. In addition government:r aren't achieving the long term savings they hoped 
for and patients are often denied access to the newest drugs for years after they are available to 
the rest of the world Yes many individllals existing and surviving on limited means financially 
may view this paradigm in a crisis mode however, these price hikes ore warranted 
2. If "Yes, you do believe there exists a crisis," what do you believe is the main contributor, the 
Phannaccutical industry seeking to maximize profits, or the current lack of a Federal policy to regulate 
prices? 
In my eyes the main contributors that have driven this crisis into existence during this ero of 
healthcare delivery are rotes of growth in pharmaceutical spending in many markets with 
widespread interventions have been no different from those in markets with few so why decrease 
the source of profitable funding? 
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Secondly widespnad access to new drugs for widely under-treaJed conditions such as heart 
disease and depression have been delayed in many countries thal have priu control policies in 
place. 
3. Do you believe that a policy that imposes caps on prescription prices will have a negative effect upon 
Pharmaceutical industry investment in rcscarch and development? Why or Why Not? 
Yes I believe that policies that impose caps on prescription prices will have negative 
repercussions upon the pharmaceutical industry irrvestment in research. developmenl and twerall. 
For example, Japan, which has severe mark.et restrictions, has less access to new medical 
therapies than any other G-7 nation. Of the 230 new pharmaceutical products launched around 
the world since 1985, more than half are not available in Japan. In the United Kingdom, stat ins, 
an important new weapon in the fight against high cholesterol and heart disease, are prescribed 
Jess lhan half as often as they are in the United States. 
4. In your opinion, what is the single most important item a government policy on prescription drug prices 
must contain? 
The adoption of policia that encourage research into new products but control health care costs 
in the Jong run is a crucial component to incorporate within the government policy on prescription 
drug prices. Innovation will be rewarded and cost savings achieved if producers are allowed to 
recoup research investments early in a product's life cycle in exchange for tighter controls later. 
In addition, the encouragement of policies that create greater access to treatments so doctors and 
physicians, not government bureaucrats, are making treatment decisions should be emphasized 
and strengthened 
Ms. Burdsy admits that some individuals are existing in a "crisis mode," however, price hikes arc 
necessary. Crisis, as she states, is in the "eyes of the beholder." Ms. Burdsy states that the use of price 
caps will have a negative effect upon research and development and will cause restricted access to new 
therapies. The items that a federa1 drug policy must include, says Ms. Burdsy, is an encouragement to 
invest in research and rewards innovation and cost control. Ms. Burdsy's opinions are in line with my own, 
supporting my stance that there does not exists a wide-spread crisis concerning phannaceutical costs. and 
that caps are not an acceptable answer. 
Next, we look at the response of Dr. Raul Abad, V.P. Medical Affairs: 
I. Do you believe that there does or docs not exist a state of crisis regarding prescription drug prices and 
their effects upon those on a fixed income? Why or Why Not? 
Yes, there is a crisis. The prices keep going up and the average income. especially elderly, 
remains the same. Many more drugs are being prescribed and patients have to get what has been 
prescribed for them. 
2. If "Y cs, you do believe there exists a crisis," what do you believe is the main contributor, the 
Phannaceutical industry seeking to maximize profits, or the current lack of a Federal policy to regulate 
prices? 
Primary is the pharmaceutical industry seeking to maximize profits. Secondary is the geMric 
medications that are sometimes not really the same as what was ordered. 
3. Do you believe that a policy that imposes caps on prescription prices will have a negative effect upon 
Phannaceutical industry investment in research and development? Why or Why Not? 
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Yu, it would have a negative effect becawe It will cut baclc on the capital available for ruearch. 
The first thing that ts CUI is always research and development. 
4. In your opinion, what is the single most important item a government policy on prescription drug prices 
must contain? 
The Federal govemmenJ would impose a certain percefllage on the base price marhq,, no/ 
necessarily a cap to only charge certain amounJs. Also, utilize a certain percentage for research 
and development. 
Dr. Abad supports the stance that there does exist a crisis. Perhaps this is because, in his past experience as 
a practicing neurosurgeon, he has been involved with first-hand situations of patients unable to afford 
prescriptions. He does; however, agree that price caps and restrictions are not the answer. His suggested 
policy using profit percentage caps is interesting. This is similar to the utility industry, where profits are 
held in line in such a way. Perltaps this could be a viable option, but only if the industry itself is allowed to 
participate in the setting of such percentages. Otherwise, I believe they will have the same negative effects 
as outright price capping. 
The next questionnaire contains the responses of Dr. Veronica Santilli. 
I. Do you believe that there does or does not exist a state of crisis regarding prescription drug prices and 
their effects upon those on a fixed income? Why or Why Not? 
By and large, there really is no crisis regarding prescription drug prices. There are those, however, who 
would lilce the government to provide prescription benefits to Medicare patients and have exaggerated the 
inability of those onfu:ed incomes to access the drugs they need. My reasons are as follows: 
• All Medicare patienJs have the option to opt for Medicare Managed Care Plan, which provides an 
allowance for prescription drugs. 
• Many states have prescription plans, which senior citizens can participate in/or a small premium. 
In New Yorlc State, senior citizens can subscribe for the Epic Program, through which prescription 
drugs can be obtained for small or no co-pays. 
• Truly indigent patienJs are eligible for Medicaid coverage in addition to Medicare. These patients 
do not pay for drugs. 
• Physicians always have samples in office that they give free of charge to those without 
prescription coverage. 
• Generic prescription drugs, which are comparable to brand names, can be obtained at reduced 
cost. 
• Several senior citizens onf,xed incomes have ability to access their drugs through wholesale 
pharmacy concerns/or small service charges through their union or as part of their retirement 
benefits. 
2. If "Yes, you do believe there exists a crisis," what do you believe is the main contributor, the 
Pharmaceutical industry seeking to maximize profits or the current lack of a Federal policy to regulate 
prices? 
Those who believe that there is an existing prescription drug crisis for suiiors on fixed incomes are mainly 
concerned with the laclc of federal regulation of drug prices and laclc of prescription drugs as part of the 
benefit package of Medicare. 
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3. Do you believe that a policy that imposes caps on prescription prices will have a negative effect upon 
Phannaceutical industry investment in research and development? Why or Why Not? 
1 absolutely believe that any cap or other regidalory activity on prescription drug prices defmitely will 
thwart the research into and development of new drugs. Pharmaceutical companies an: primarily 
interested in profits. These profits are distributed to stockholders in part, but much of these proflls are put 
back into new drug research. it is more important to urge the pharmoceuJlcal companies to develop 
voluntary programs (grants), which would allow qualified patients to receive company sponsored discounls 
on drugs. in additions the companies can pruvide vouchers, which could be distributed through providers 
of health services, senior centers and pharmacies. The federal government should urge and facilitate the 
development of quality generic drug substitutes and encourage physicians to prescribe these, when 
feasible. 
4. In your opinion, what is the single most important item a government policy on prescription drug prices 
must contain? 
The most important item, which any government policy on prescription drugs needs to contain, is the Drug 
companies, which can demonstrate that they are willing to work with consumers, directly or through state 
subsidized prescription programs, should be given recognition through tax relief, special creaJion of a 
system which provides for greater competition among producers of pharmaceutical, consideration by the 
FDA and recognition for their humanitarian activities. 
Dr. Santilli supports my opinion that there does not exist a state of crisis. I was surprised at this, believing 
that she would share the stance of fellow physician, Dr. Abad, due to her first hand experience with 
patients. Her answer to question three is quite interesting, specifically in her suggestions that 
phannaceutical companies take on a voluntary stance on price discounting and her thoughts on the 
government promotion of generic drug production. 
The following are the responses submitted on behalf of the Cedar Grove Mayor, Mr. Joseph Torlucci: 
l. Do you believe that there does or does not exist a state of crisis regarding prescription drug prices and 
their effects upon those on a fixed income? Why or Why Not? 
I do believe there is a state of crisis regarding prescription dn,g prices .... ] base this 
determination on personal knowledge with family, including 2 elderly parents. 
2. lf "Yes, you do believe there exists a crisis," what do you believe is the main contributor, the 
Phannaceutica1 industry seeking to maximize profits, or the current lack of a Federal policy to regulate 
prices? 
I do not necessarily believe that the industry tries to "maximize profits"· yet there certainly is a 
need for more governmental intervention. 
3. Do you believe that a policy that imposes caps on prescription prices will have a negative effect upon 
Phannaceutical industry investment in research and development? Why or Why Not? 
Caps, if not reasonably set - certainly will curtail R &: D. 
4. In your opinion, what is the single most important item a government policy on prescription drug prices 
must contain? 
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Permitting a drug company to extend patents on drugs in �hangefor creating cost controls to 
the benefit of comumers. 
The responses ofMayor surprised me. As a politician, I thought there would be support for increased 
government intervention; However, a very interesting idea was his patent extension grant in return for the 
industry to cut its own costs. I can see where this would serve as a great incentive for cuts - it gives the 
industry two things: the patents it needs to maximize their profits longer on individual products as well as 
an opportunity for implementing a cost program themselves. This strikes me as a rather mild form of 
intervention worth looking into further. 
Representatives O' Toole and Pascrell chose not to participate in this project After first contacting them 
by mail, then later by phone, both offices refrained from providing comments on this issue. Perhaps due to 
its controversial nature and the timelines of the politics involved, there was some fear that providing formal 
responses could come back and haunt them. This was quite disappointing. Their comments would have 
been interesting and important, giving insight into the politics behind my topic. The responses of the Mayor 
of Cedar Grove did; however, show me a bit of this. 
To conclude, I had thought prior to receiving the completed questionnaires, that there would be less 
agreement in the responses. I had expected that the pharmaceutical representative would fall to the left side, 
denying any crisis, and that the politicians would fall to the far right, claiming the existence of an extreme 
crisis, blaming the pharmaceutical industry. I also thought the physicians would fall somewhere in between. 
Looking at the opinions, there is no extreme left or right. 
It is important to note that each interviewee; although approaching the questions from varying 
perspectives, all agree that caps on pharmaceutical prices arc not the answer to the problem of high costs. 
All agree that this would do more harm than good, negatively affecting research and development. 
There is disagreement on the existence or level of crisis; however, each provides interesting ideas as to 
what future legislation must include in order to be effective. Overall, I was quite satisfied with the results of 
this partofmy study. 
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Closing Notes 
The media coverage and the statistics out there tell us that there exists a crisis in this country concerning 
the high cost of prescription prices on those on a fixed income. The industries and politicians argue back 
and forth as to why and how great. By looking at my sample, one really cannot soc: a crisis. If this sample is 
a fairly good representation of the population of this country, then perhaps the crisis is not as great as we're 
led to believe. I do think that this is a good representation of the high population, suburban, Northeast 
portion of the United States. Any future studies into this situation must use a sample similar to mine - one 
that is suburban and as "average" as possible. Using lower-income, inner city or too affluent a sample 
would generate unrealistic, skewed data. It would be interesting to sample similar populations from varying 
regions of the country to compare and contrast the data for more complete conclusions. I do think that this 
study was weak due to its limit to one sample. 
As generations become less dependent upon Social Security for their retirement and also are more open to 
less costly managed care programs, I believe the "crisis" perceived will lessen. Price caps and restrictions 
are not the answer. By tying the hands of industry, inevitably it is the consumer who will suffer. Cut the 
profits for the phannaceutical industry and they will answer with a cut to research and development as well 
as the production of drugs for less-profitable and more rare conditions. 
Certainly, there are areas that need improvement, and everyone would benefit from some sort of policy 
change concerning certain costs of medications. By looking at this simple survey, the results show us an 
important fact, namely that many of those falling into this age group suffer from the same conditions. 
Therefore, any future policy should focus upon these conditions. Why couldn't a plan support subsidies for 
high blood pressure and arthritis's medications? Or, perhaps there could be a subsidy plan that uses a scale 
approach covering more for common- ailment prescriptions and scaling down for lesser. Answers can be 
found that are more industry-friendly. In the writing of future policy, it would be in the best interest of all 
parties if it were co-written by three parties - the Federal government, the AARP and a representative board 
from the pharmaceutical industry. Any policy writing that shuts out the pharmaceutical industry or a body 
representing the elderly would generate regulations that would damage both groups. 
18 
I. Stuart, Bruce, (Winter 2001200 l ). How Medicare beneficiaries pay for prescription dnt�. 
Generations, 24. 62-68. 
2. Anonymous, (November 1997). Restricting dntg choice can increase health care usage. Employee 
Benefit Plan Review, 52. 45. 
3. Greenberg, Daniel S., (January 8, 2000). Drug pricing "powder keg" stirs up US health-care politics. 
The Lancet, 355. 125. 
4. Anonymous, (June 2000). Editor's pick.. Western Journal of Medicine, 172. 353. 
5. ThralL Thcrcsc Hudson. (August 2000). Biller pills. Hospital and Health Networks, 74. 48-52. 
6. Mueller, Curt; Schur, Claudia; O'Connell, Joan, (October 1997) Prescription dntg spending: The 
impact of age and chronic disease status. American Journal of Public Health, 87. 1626-1629. 
7. Wechsler, Jill, (January 2000). Prices, patents, risks and research. Phannacc:utical Technology, 24. 12- 
17. 
8. Cauchi, Richard, (January 2001). State's Rx for drug costs. State Legislatures, 27. 20-23. 
9. Avom, Jerry; Monette, Johanne; Lacour, Anne; Bohn, Rhonda L., (May 13, 1998). Persistence of use 
oflipid-lowering medications: A cross-nationaJ study. JAMA, 279. 1458-1462. 
JO. Goozner, Menill, (September 11, 2000). The price i.sn 't right. The American Prospect, l l. 25-29. 
/ I. Long, Stephen H., (Spring 1994). Prescription drugs and the elderly: Issues and options. Health 
Affairs, 13. 2-13. 
12. Danzon. Patricia M., (2000) Making sense of drug prices. Regulation, 23. 56-63. 
13. Sandow, Doug, (November 2000). Our phoniest drug war. The American Spectator, 33. 74- 76. 
19 
EXHIBITS 
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EXHIBIT 1 
Geographic Sample Area Demographics 
Cedar Grove, New Jersey 
(1990 U.S. Census Data) 
Population (1996 estimate): 
Race: 
White: 
African American: 
Other: 
Median Age: 
65 and Older: 
Number of Households with persons over 65: 
Number of Households Receiving Social Security: 
11,731 
94.62% 
2.32% 
3.08% 
41.80 Years 
21.23% 
1,361 
1,351 
Per Capita Income: 
Median Household Income: 
Number of Persons in Poverty: 
Median Value of a Single Family Home: 
$23,052 
$55,464 
332 
$213,300 
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EXHIBITS 
Justine Maiello 
Seton Hall University 
Capstone Project: Survey of the impact of increased pharmaceutical costs on 
retirees on a fixed income 
This survey is anonymous and confidential. Feel free to skip any question 
that you do not feel comfortable answering. 
I. What is your Age? ___ Years 2. Sex: M/F 
3 .  How many years have you been retired? 
4. How long have you lived in this community? 
Years 
---- 
Years 
---- 
5. For what condition(s) do you regularly take a prescription medication? 
Please circle all that apply: Diabetes 
High Blood Pressure 
Heart Ailments 
Arthritis 
Depression 
Glaucoma 
Other (please specify) _ 
6. Have you had any of the following chronic diseases: 
Please circle all that apply: Cancer 
Heart Disease 
Respiratory Disease 
Arthritis 
Stroke 
Glandular Disorders 
Other (please specify) _ 
7. Do you participate in A.)Traditional Medicare or B.)Medicare HMO 
(please circle one) 
8. Why did you choose the plan selected in question #7? 
9. Do you have a private Medigap policy? YES I NO 
10.lfyou chose "YES" for question #9, what are you currently paying for it? 
$ /month 
11.Ifyou chose "YES" for question #9, why did you choose to participate in 
Medigap? _ 
12.Have you ever not filled a prescription due to its cost? YES I NO 
13. Have you ever rationed your medication to make your prescription last 
longer due to its cost? YES I NO 
14. Have you ever postponed paying bills or reducing food outlays due to 
the cost of your medications? YES I NO 
Thank you for your participation. If you could please return this survey in 
the attached postage-paid envelope by May 30, 2001 
